Click a link below to view the mailing archive as if it had been sent to you.
| 2024-02-29 12:15 | | Novo Nordisk's new Boston-area campus reflects 'competitive' R&D growth, and not just for GLP-1s and more... |
| 2024-02-29 00:15 | | CDC advisory panel says people 65 and older should get a Covid spring booster shot and more... |
| 2024-02-28 12:15 | | AbbVie Puts Potential $713M on the Line for OSE’s Inflammation Antibody and more... |
| 2024-02-28 00:15 | | Denali Secures $500M in Financing, Focuses on Large Molecule Biotherapeutics and more... |
| 2024-02-27 12:15 | | Viking Therapeutics' weight-loss drug trial success spurs share surge and more... |
| 2024-02-27 00:15 | | Novo Nordisk doles out $1.4B for molecular glue degraders licensing pact and more... |
| 2024-02-26 12:15 | | 6 first-half 2024 oncology data readouts to watch and more... |
| 2024-02-26 00:15 | | Amgen details rare disease ambitions following $28B Horizon acquisition and more... |
| 2024-02-23 12:15 | | Sanofi, Regeneron Secure FDA Priority Review for Dupixent in COPD and more... |
| 2024-02-23 00:15 | | Biopharma R&D Funding Has Rebounded But Clinical Trial Starts Slowed Down in 2023, Says IQVIA Institute and more... |
| 2024-02-22 12:15 | | Moderna posts surprise quarterly profit as it eyes RSV vaccine approval and more... |
| 2024-02-22 00:15 | | Small study adds to growing hope CAR-T cell therapy could revolutionize autoimmune disease treatment and more... |
| 2024-02-21 12:15 | | 4 biotechs to watch in 2024 and more... |
| 2024-02-21 00:15 | | Lilly Edges Out J&J to Top 20 BioPharma Market Cap List for 2023 and more... |
| 2024-02-20 12:15 | | AbbVie CEO Richard Gonzalez to step down, Robert Michael to succeed him and more... |
| 2024-02-19 00:15 | | FDA approves Iovance's Amtagvi as first T-cell therapy for a solid tumor and more... |
| 2024-02-16 12:15 | | Daiichi invests 1 bln eur near Munich to make precision cancer drugs and more... |
| 2024-02-16 00:15 | | Wegovy fuels sharp rise in use of weight-loss drugs for US youth and more... |
| 2024-02-15 12:15 | | Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published and more... |
| 2024-02-15 00:15 | | Sage offers encouraging details on launch of new postpartum depression pill and more... |
| 2024-02-14 12:15 | | Cancer and Neuroscience Led 2023 VC, M&A Investment in Biopharma and more... |
| 2024-02-14 00:15 | | Rocket Pharma gets FDA review extension review of gene therapy and more... |
| 2024-02-13 12:15 | | Biogen sees flat 2024 sales, pick up in Alzheimer's drug demand and more... |
| 2024-02-13 00:15 | | Novo Nordisk's controlling shareholder plans to invest about $35 bln by 2030 and more... |
| 2024-02-12 12:15 | | Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med and more... |
| 2024-02-12 00:15 | | Pfizer launches oncology ad campaign at Super Bowl LVIII and more... |
| 2024-02-09 12:15 | | Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts and more... |
| 2024-02-09 00:15 | | PBMs take bulk of blame as senators question BMS, J&J and Merck CEOs on high drug prices in US and more... |
| 2024-02-08 12:15 | | AstraZeneca’s year-end revenues rise but Wall Street remains unimpressed and more... |
| 2024-02-08 00:15 | | Drug Shortages Aren’t Over. And There’s Little Progress Toward Ending Them and more... |
| 2024-02-07 12:15 | | Eisai, Biogen likely to miss early launch goal for Alzheimer's drug Leqembi and more... |
| 2024-02-07 00:15 | | Amgen earnings boosted by Horizon deal, Gilead quarterly revenue drops and more... |
| 2024-02-06 12:15 | | Lilly expects strong 2024 profit on rising weight-loss drug demand and more... |
| 2024-02-06 00:15 | | Novartis CEO's 2023 pay rises 21% as Roche's helmsman nets $11M in his first year and more... |
| 2024-02-05 12:15 | | Novartis in the lead to acquire cancer drug developer MorphoSys-sources and more... |
| 2024-02-05 00:15 | | Biotech is the new focus in U.S.-China tech rivalry and more... |
| 2024-02-02 12:15 | | BMS more likely to bet on bolt-ons after recent buying spree and more... |
| 2024-02-02 00:15 | | Congress Passes Tax Provision Critical for Medtech R&D and more... |
| 2024-02-01 12:15 | | Sanofi expects RSV antibody to breach blockbuster status in 2024, even as supply hitch drags on and more... |
| 2024-02-01 00:15 | | Gilead invests $320M in Arcus to increase stake to 33% and more... |
